Q4 2025 Earnings Summary
Metric | YoY Change | Reason |
---|---|---|
General & Administrative Expenses | -$6M to -$8M | The restatement process reduced previously overstated expenses by $6M–$8M for fiscal 2023, which in turn increased net income in the current period compared to prior periods |
Sales Tax Liabilities | Adjustment: $16M to $23M increase | A correction in the accounting approach for sales tax liabilities—shifting from a “probable and estimable” method to recognizing the maximum legal potential liability—resulted in an upward adjustment of $16M–$23M compared to earlier period estimates |
Net Income | Increase (implied) | Due to the reduction in general and administrative expenses from the restatement, net income increased in the current period relative to previous periods, demonstrating the effect of correcting historical accounting errors |
Revenue and Cash | No change | Despite the restatement adjustments, revenue, cost of goods sold, and cash balances (with cash and equivalents reported at $49.4M) remained unaffected, indicating that the corrections were technical adjustments rather than operational shifts |
Research analysts covering PETMED EXPRESS.